Table 4

Discriminative capacity of response criteria

IMPACT	Placebo (n = 52)	Active drug (n = 52)	χ²_MH	p Value
Response criteria	% improved	% improved	χ²_MH	p Value
EULAR28			53.4	<0.001
Good+moderate	26	92%
Good	0	60
EULAR			48.6	<0.001
Good+moderate	26	88
Good	0	63
ACR20	10	67	36.2	<0.001
ACR50	0	48	32.6	<0.001
ACR70	0	29	17.4	<0.001
PsARC	30	82	27.9	<0.001
ΔDAS28>1.2	13	83	49.4	<0.001
ΔDAS>1.2	10	67	36.2	<0.001
Low-disease activity criteria	% reached	% reached	χ²_MH	p Value
DAS28⩽3.2	4	61	35.3	<0.001
DAS⩽2.4	8	65	33.4	<0.001
OMERACT MDAS	6	50	25.1	<0.001
DAS28⩽2.6	2	41	21.2	<0.001
DAS⩽1.6	0	35	20.0	<0.001

Etanercept	Placebo (n = 30)	Active drug (n = 30)	χ²_MH	p Value
Response criteria	% improved	% improved	χ²_MH	p Value
ACR, American College of Rheumatology; DAS, Disease Activity Score; EULAR, European League Against Rheumatism; IMPACT, Infliximab Multinational Psoriatic Arthritis Controlled Trial; MDAS, minimal disease activity in rheumatoid arthritis; OMERACT, Outcome Measures in Rheumatoid Arthritis Clinical Trials; PsARC, psoriatic arthritis response criteria; χ²_MH, χ² Mantel Haenszel.
EULAR28			26.2	<0.001
Good+moderate	15	93
Good	8	59
EULAR			24.1	<0.001
Good+moderate	19	89
Good	4	44
ACR20	15	73	19.6	<0.001
ACR50	4	50	14.8	0.001
ACR70	0	13	3.8	0.05
PsARC	33	90	19.3	<0.001
ΔDAS28>1.2	7	80	32.2	<0.001
ΔDAS>1.2	7	60	18.9	<0.001
Low-disease activity criteria	% reached	% reached	χ²_MH	p Value
DAS28⩽3.2	11	69	19.0	<0.001
DAS⩽2.4	15	69	16.4	<0.001
OMERACT MDAS	7	63	20.8	<0.001
DAS28⩽2.6	11	59	13.5	0.002
DAS⩽1.6	4	45	12.4	0.004